{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:22:27Z","timestamp":1790335347929,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:00:00Z","timestamp":1334016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We report the use of sorafenib and bevacizumab in combination for a patient with recurrent metastatic hepatoblastoma (HB). This combination demonstrated activity against our patient's refractory HB that had been extensively treated with multiple prior chemotherapeutic regimens. The patient had stabilization of radiographic disease coupled with an 83% decrease in his alpha\u2010fetoprotein level. Given the response in this setting and the paucity of other available options, consideration could be given to using this combination as therapy in patients with recurrent HB who have failed more traditional agents. Pediatr Blood Cancer 2012; 59: 939\u2013940. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/pbc.24171","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T14:58:28Z","timestamp":1334069908000},"page":"939-940","source":"Crossref","is-referenced-by-count":24,"title":["Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP"],"prefix":"10.1002","volume":"59","author":[{"given":"Anne M.","family":"Marsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Feusner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,10]]},"reference":[{"key":"e_1_2_3_2_2"},{"key":"e_1_2_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61904-7"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25327"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_3_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_3_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.017"},{"key":"e_1_2_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"e_1_2_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_3_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.8332"},{"key":"e_1_2_3_13_2","doi-asserted-by":"crossref","first-page":"Abstr 4113","DOI":"10.1200\/jco.2011.29.15_suppl.4113","article-title":"Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801)","volume":"29","author":"Castellano DE","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605514"},{"key":"e_1_2_3_15_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i28.3592"},{"key":"e_1_2_3_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.9230"},{"key":"e_1_2_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10177"},{"key":"e_1_2_3_18_2","doi-asserted-by":"crossref","first-page":"Abstr e14549","DOI":"10.1200\/jco.2009.27.15_suppl.e14549","article-title":"Bioavailability of sorafenib tablets administered as a liquid suspension","volume":"27","author":"Lettieri JT","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_3_19_2","doi-asserted-by":"crossref","first-page":"Abstr 9550","DOI":"10.1200\/jco.2010.28.15_suppl.9550","article-title":"Sorafenib, gamma\u2010secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma","volume":"28","author":"Sanchez\u2010Diaz PC","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22187"},{"key":"e_1_2_3_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/jpsu.2003.50099"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24171","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T10:30:52Z","timestamp":1696847452000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,10]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/pbc.24171"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24171","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,10]]}}}